Strong U.S. Performance
The U.S. market showed strong performance across all segments, with significant growth in pharmaceutical diagnostics, multiyear enterprise deals in imaging products, and solid PDx revenue performance.
Growth in Backlog
The company reported a healthy backlog of $19.6 billion, up $1.2 billion year-over-year, driven primarily by services, with a company book-to-bill ratio of 1.04x.
Adjusted EBIT Margin Increase
The adjusted EBIT margin increased by 90 basis points year-over-year to 16.3%, and the adjusted EPS was up by 15% year-over-year.
Pharmaceutical Diagnostics Growth
Pharmaceutical Diagnostics (PDx) segment delivered 7% year-over-year organic growth with an EBIT margin of approximately 31%.
Free Cash Flow Improvement
The company generated free cash flow of $651 million, up $81 million year-over-year, with improvements in working capital management efficiency.
Innovation and Partnerships
GE HealthCare secured FDA clearance for a new theranostics software tool and established a center of excellence in Germany, leading a $28 million initiative to expand its use.